252 related articles for article (PubMed ID: 7492790)
1. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.
Richardson DR; Tran EH; Ponka P
Blood; 1995 Dec; 86(11):4295-306. PubMed ID: 7492790
[TBL] [Abstract][Full Text] [Related]
2. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
Richardson DR; Milnes K
Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
[TBL] [Abstract][Full Text] [Related]
3. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
Becker E; Richardson DR
J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
[TBL] [Abstract][Full Text] [Related]
4. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
5. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.
Richardson DR
Biochim Biophys Acta; 1997 May; 1320(1):45-57. PubMed ID: 9186779
[TBL] [Abstract][Full Text] [Related]
6. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
Richardson DR; Ponka P
J Lab Clin Med; 1994 Nov; 124(5):660-71. PubMed ID: 7964124
[TBL] [Abstract][Full Text] [Related]
7. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
Baker E; Vitolo ML; Webb J
Biochem Pharmacol; 1985 Sep; 34(17):3011-7. PubMed ID: 4038321
[TBL] [Abstract][Full Text] [Related]
8. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
9. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
Richardson D; Ponka P; Baker E
Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
[TBL] [Abstract][Full Text] [Related]
10. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
[TBL] [Abstract][Full Text] [Related]
11. Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia.
Richardson DR
Leuk Lymphoma; 1998 Sep; 31(1-2):47-60. PubMed ID: 9720714
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities.
Richardson DR
Antimicrob Agents Chemother; 1997 Sep; 41(9):2061-3. PubMed ID: 9303419
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate.
Chitambar CR; Boon P; Wereley JP
Clin Cancer Res; 1996 Jun; 2(6):1009-15. PubMed ID: 9816262
[TBL] [Abstract][Full Text] [Related]
14. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.
Gao J; Richardson DR
Blood; 2001 Aug; 98(3):842-50. PubMed ID: 11468187
[TBL] [Abstract][Full Text] [Related]
15. Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes.
Buss JL; Arduini E; Ponka P
Biochem Pharmacol; 2002 Dec; 64(12):1689-701. PubMed ID: 12445858
[TBL] [Abstract][Full Text] [Related]
16. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate.
Hermes-Lima M; Ponka P; Schulman HM
Biochim Biophys Acta; 2000 Oct; 1523(2-3):154-60. PubMed ID: 11042379
[TBL] [Abstract][Full Text] [Related]
17. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells.
Buss JL; Arduini E; Shephard KC; Ponka P
Biochem Pharmacol; 2003 Feb; 65(3):349-60. PubMed ID: 12527328
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture.
Baker E; Richardson D; Gross S; Ponka P
Hepatology; 1992 Mar; 15(3):492-501. PubMed ID: 1544632
[TBL] [Abstract][Full Text] [Related]
19. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone.
Ponka P; Grady RW; Wilczynska A; Schulman HM
Biochim Biophys Acta; 1984 Dec; 802(3):477-89. PubMed ID: 6509088
[TBL] [Abstract][Full Text] [Related]
20. Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes.
Ponka P; Schulman HM; Wilczynska A
Biochim Biophys Acta; 1982 Oct; 718(2):151-6. PubMed ID: 7138909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
